ALNY:NSD-Alnylam Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 160.42

Change

+0.42 (+0.26)%

Market Cap

USD 18.21B

Volume

0.83M

Average Target Price

USD 147.67 (-7.95%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.alnylam.com

Address : 675 West Kendall Street, Cambridge, MA, United States, 02142

Employees : 1,323

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.85

52 Week High : 164.09

Short Ratio : 8.60

52 Week Low : 69.11

Shorted Shares : 5,851,089

200 Day Moving Average : 125.64

Shorted Shares Previous Month : 5,234,769

50 Day Moving Average : 140.55

Shares Held By Insiders : 8.01%

Short Percentage : 5.00%

Shares Held by Institutions : 94.73999999999999%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-3.14 (-1.05%)

 USD76.11B 50.45 37.87
REGN Regeneron Pharmaceuticals, Inc

-0.54 (-0.08%)

 USD65.50B 31.28 21.67
SGEN Seattle Genetics, Inc

-0.61 (-0.35%)

 USD30.38B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-4.46 (-3.97%)

 USD23.85B 10.60 9.11
INCY Incyte Corporation

-0.38 (-0.35%)

 USD23.62B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

+0.75 (+0.59%)

 USD23.14B 201.24 120.72
MRNA Moderna, Inc

+0.49 (+0.80%)

 USD22.86B N/A N/A
GMAB Genmab A/S

+0.86 (+2.50%)

 USD22.35B 60.04 6.37
BNTX BioNTech SE

-1.78 (-2.57%)

 USD15.72B -99,999.99 N/A
BGNE BeiGene, Ltd

+7.51 (+3.82%)

 USD15.64B N/A N/A

ETFs Containing ALNY

Symbol Name Weight Mer Price(Change) Market Cap
BTEC Principal Healthcare Inno.. 2.88 % 0.42 %

+0.74 (+1.63%)

 USD0.09B
FXH First Trust Health Care A.. 2.43 % 0.62 %

+0.58 (+0.63%)

 USD1.93B
FHH:CA FT AlphaDEX U.S. Health C.. 2.36 % 0.70 %

-0.30 (-0.88%)

 USD0.02B
XBI SPDR S&P Biotech ETF 1.88 % 0.35 %

+1.73 (+1.50%)

 USD4.91B
ZHU:CA BMO Equal Weight US Healt.. 1.86 % 0.35 %

+0.41 (+1.11%)

 USD0.03B
ZUH:CA BMO Equal Weight US Healt.. 1.85 % 0.35 %

+0.12 (+0.19%)

 USD0.39B
SCHM Schwab U.S. Mid-Cap ETF 0.54 % 0.04 %

+0.37 (+0.71%)

 USD6.06B
IUSZ:LSE iShares Edge MSCI USA Siz.. 0.42 % 0.20 %

-0.11 (-1.61%)

 USD0.06B
IWSZ:LSE iShares Edge MSCI World S.. 0.16 % 0.30 %

-0.45 (-1.39%)

 USD0.60B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.29% 73% C 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.29% 73% C 84% B
Trailing 12 Months  
Capital Gain 119.03% 84% B 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 119.03% 84% B 92% A-
Trailing 5 Years  
Capital Gain 38.25% 76% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.25% 75% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 26.00% 70% C- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.00% 70% C- 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 77.64% 23% F 10% F
Risk Adjusted Return 33.49% 65% D 42% F
Market Capitalization 18.21B 98% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 12.66 14% F 10% F
Price / Cash Flow Ratio -65.42 97% A+ 95% A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -61.20% 55% F 21% F
Return on Invested Capital -67.88% 46% F 14% F
Return on Assets -27.97% 53% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.60 18% F 11% F
Short Percent 7.06% 42% F 30% F
Beta 1.85 36% F 18% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.